

# Denis Jullien

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3830111/publications.pdf>

Version: 2024-02-01

130  
papers

7,021  
citations

61687

45  
h-index

71088

80  
g-index

149  
all docs

149  
docs citations

149  
times ranked

7519  
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment of Eosinophilic Annular Erythema: Retrospective multicenter study and literature review. <i>Annales De Dermatologie Et De Venereologie</i> , 2022, 149, 123-127.	0.5	6
2	Incidence and severity of COVID-19 in patients with autoimmune blistering skin diseases: A nationwide study. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 494-497.	0.6	18
3	Clinical efficacy of selective JAK1 inhibition and transcriptome analysis of chronic discoid lupus erythematosus. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	1.3	3
4	The Prevalence and Disease Characteristics of Generalized Pustular Psoriasis. <i>American Journal of Clinical Dermatology</i> , 2022, 23, 5-12.	3.3	28
5	Vaccine hesitancy and access to psoriasis care during the COVID-19 pandemic: findings from a global patient-reported cross-sectional survey. <i>British Journal of Dermatology</i> , 2022, 187, 254-256.	1.4	11
6	International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis. <i>JAMA Dermatology</i> , 2022, 158, 561.	2.0	12
7	Palmoplantar pustulosis and acrodermatitis continua of Hallopeau: demographic and clinical comparative study in a large multicentre cohort. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 1578-1583.	1.3	11
8	Impact of Childhood Onset Psoriasis on Addictive Behaviours, Socioeconomic and Educational Data in Adulthood. <i>Acta Dermato-Venereologica</i> , 2022, 102, adv00733.	0.6	2
9	Switches between biologics in patients with moderate-to-severe psoriasis: results from the French cohort PSOBIOSEQ. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 2101-2112.	1.3	8
10	Distal phalangeal bone erosions observed by HR-pQCT in patients with psoriatic onycholysis. <i>Rheumatology</i> , 2021, 60, 1176-1184.	0.9	5
11	Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry-based study. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 60-71.	1.5	136
12	Psoriasis: frequency and reasons for absenteeism results from a study on 1609 active patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e301-e303.	1.3	3
13	A recent nodule on the forehead. <i>European Journal of Dermatology</i> , 2021, 31, 117-119.	0.3	0
14	Massive clonal expansion of polyclonal skin and blood CD8 <sup>+</sup> T cells in patients with toxic epidermal necrolysis. <i>Science Advances</i> , 2021, 7, .	4.7	20
15	Risk-mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey*. <i>British Journal of Dermatology</i> , 2021, 185, 80-90.	1.4	26
16	Practical management of patients on anti-IL17 therapy: Practical guidelines drawn up by the Club Rhumatismes et Inflammation (CRI). <i>Joint Bone Spine</i> , 2021, 88, 105210.	0.8	0
17	Practical management of patients on anti-TNF therapy: Practical guidelines drawn up by the Club Rhumatismes et Inflammation (CRI). <i>Joint Bone Spine</i> , 2021, 88, 105174.	0.8	0
18	Chilblain-like lesions after BNT162b2 mRNA COVID-19 vaccine: a case report suggesting that COVID toes are due to the immune reaction to SARS-CoV-2. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e630-e632.	1.3	20

#	ARTICLE	IF	CITATIONS
19	Low incidence rate of respiratory and viral infections over 5 years of treatment with tildrakizumab in patients with moderate-to-severe psoriasis: pooled analysis from reSURFACE 1 and reSURFACE 2 phase 3 trials. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e709-e711.	1.3	2
20	Characteristics of patients with psoriasis with Psoriasis Area and Severity Index &lt; 10 treated with biological agents: results from the French PsoBioTeq cohort. <i>British Journal of Dermatology</i> , 2021, 185, 1052-1054.	1.4	2
21	Describing the burden of the COVID-19 pandemic in people with psoriasis: findings from a global cross-sectional study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e636-e640.	1.3	18
22	Outcome of pretransplant melanoma after solid organ transplantation: an observational study. <i>Transplant International</i> , 2021, 34, 2154-2165.	0.8	0
23	First-Line Biologic Therapy and Obesity in Moderate-to-Severe Psoriasis: Results from the Prospective Multicenter Cohort PsoBioteq. <i>Dermatology</i> , 2021, 237, 338-346.	0.9	5
24	Condyloma acuminatum of the nipple, an unusual presentation. <i>European Journal of Dermatology</i> , 2021, 31, 586-588.	0.3	0
25	Evolution of Drug Survival with Biological Agents and Apremilast Between 2012 and 2018 in Psoriasis Patients from the PsoBioTeq Cohort. <i>Acta Dermato-Venereologica</i> , 2021, , .	0.6	4
26	Users of biologics in clinical practice: would they be eligible for phase III clinical studies? Cohort Study in the French Psoriasis Registry PSOBIOTEQ. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 293-300.	1.3	36
27	Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect. <i>British Journal of Dermatology</i> , 2020, 182, 1111-1119.	1.4	55
28	Chilblain-like acral lesions during the COVID-19 pandemic (‘‘COVID toes’’): Histologic, immunofluorescence, and immunohistochemical study of 17 cases. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 870-875.	0.6	121
29	COVID-19 and outbreak of chilblains: are they related?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e757-e758.	1.3	14
30	Efficacy and safety of <sc>TNF</sc> blockers and of ustekinumab in palmoplantar pustulosis and in acrodermatitis continua of Hallopeau. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2330-2338.	1.3	13
31	Real-world evidence of secukinumab in psoriasis treatment ‘‘ a meta-analysis of 43 studies. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1174-1185.	1.3	46
32	Factors Associated With Short-term Relapse in Patients With Pemphigus Who Receive Rituximab as First-line Therapy. <i>JAMA Dermatology</i> , 2020, 156, 545.	2.0	40
33	Long-Term Infliximab Treatment in Psoriasis Patients: A National Multicentre Retrospective Study. <i>Dermatology Research and Practice</i> , 2020, 2020, 1-3.	0.3	3
34	High prevalence of cannabis use among patients with hidradenitis suppurativa: results from the VERADDICT survey. <i>British Journal of Dermatology</i> , 2019, 181, 839-841.	1.4	12
35	Biosimilars for Psoriasis ‘‘Experience from Europe. <i>Current Dermatology Reports</i> , 2019, 8, 26-34.	1.1	6
36	Large International Validation of ABSIS and PDAI Pemphigus Severity Scores. <i>Journal of Investigative Dermatology</i> , 2019, 139, 31-37.	0.3	55

#	ARTICLE	IF	CITATIONS
37	Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 251-265.e19.	0.6	362
38	Clinical and Therapeutic Aspects of Linear Psoriasis: A Study of 30 Cases. <i>American Journal of Clinical Dermatology</i> , 2018, 19, 609-615.	3.3	9
39	Psoriatic arthritis screening by the dermatologist: development and first validation of the <i>PURE</i> 4 scale™. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 1.3 1950-1953.		26
40	Oral ofloxacin and clindamycin as an alternative to the classic rifampicin-clindamycin in hidradenitis suppurativa: retrospective analysis of 65 patients. <i>British Journal of Dermatology</i> , 2018, 178, e15-e16.	1.4	18
41	sQUIZ your knowledgeÇf: A recent red lesion on the forearm. <i>European Journal of Dermatology</i> , 2018, 28, 280-282.	0.3	0
42	New-onset vitiligo and progression of pre-existing vitiligo during treatment with biological agents in chronic inflammatory diseases. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 181-186.	1.3	57
43	Predictors of long-term drug survival for infliximab in psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 96-101.	1.3	15
44	Incidence and prevalence of psoriatic arthritis in Denmark: a nationwide register linkage study. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1591-1597.	0.5	52
45	The Clinical Relevance of Antifibrillar (anti-RNP) Autoantibodies in Systemic Sclerosis. <i>Scandinavian Journal of Immunology</i> , 2017, 85, 73-79.	1.3	23
46	Factors associated with the choice of the first biologic in psoriasis: real-life analysis from the Psobioteg cohort. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 2046-2054.	1.3	30
47	First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. <i>Lancet</i> , The, 2017, 389, 2031-2040.	6.3	438
48	Risk of Aggressive Skin Cancers After Kidney Retransplantation in Patients With Previous Posttransplant Cutaneous Squamous Cell Carcinomas. <i>Transplantation</i> , 2017, 101, e133-e141.	0.5	24
49	Increasing incidence of melanoma after solid organ transplantation: a retrospective epidemiological study. <i>Transplant International</i> , 2017, 30, 1172-1180.	0.8	32
50	337 Long-term clinical outcomes after 2 years of Ixekizumab treatment in patients with moderate-to-severe psoriasis with a focus on absolute PASI. <i>Journal of Investigative Dermatology</i> , 2017, 137, S58.	0.3	4
51	sQUIZ your knowledge! Persistent facial plaques. <i>European Journal of Dermatology</i> , 2017, 27, 681-683.	0.3	0
52	Management of psoriatic arthritis among cutaneous psoriasis patients: from pathogenesis to therapy. <i>Italian Journal of Dermatology and Venereology</i> , 2017, 152, 458-473.	0.1	0
53	Active tuberculosis in psoriasis patients treated with TNF antagonists: a French nationwide retrospective study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 1336-1341.	1.3	16
54	Bioterapias en dermatología (cáncer no incluido). <i>EMC - Dermatología</i> , 2016, 50, 1-12.	0.1	0

#	ARTICLE	IF	CITATIONS
55	Hidradenitis suppurativa (HS): An unrecognized paradoxical effect of biologic agents (BA) used in chronic inflammatory diseases. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 1153-1159.	0.6	56
56	Development and psychometric validation of the REFlective evaluation of psoriasis Efficacy of Treatment and Severity ( REFLETS ) questionnaire: a common measure of plaque-type psoriasis severity and treatment efficacy for patients and clinicians. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 498-506.	1.3	10
57	Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: Systematic review and meta-analysis. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, 242-248.	0.6	222
58	Acrodermatitis Continua of Hallopeau Treated Successfully with Ustekinumab and Acitretin after Failure of Tumour Necrosis Factor Blockade and Anakinra. <i>Dermatology</i> , 2015, 230, 97-100.	0.9	23
59	The Clinical Spectrum and Therapeutic Management of Hypocomplementemic Urticarial Vasculitis: Data From a French Nationwide Study of Fifty-seven Patients. <i>Arthritis and Rheumatology</i> , 2015, 67, 527-534.	2.9	136
60	Immunogenicity of Biotherapy Used in Psoriasis: The Science Behind the Scenes. <i>Journal of Investigative Dermatology</i> , 2015, 135, 31-38.	0.3	77
61	Treatment (biotherapy excluded) of psoriatic arthritis: an appraisal of methodological quality of international guidelines. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 33-39.	1.3	6
62	Is there a psoriasis skin phenotype associated with psoriatic arthritis? Systematic literature review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 17-26.	1.3	72
63	Evidence-based recommendations on the role of dermatologists in the diagnosis and management of psoriatic arthritis: systematic review and expert opinion. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 3-12.	1.3	25
64	Skin Cancers After Liver Transplantation. <i>Transplantation</i> , 2014, 98, 335-340.	0.5	33
65	Symptoms dermatologists should look for in daily practice to improve detection of psoriatic arthritis in psoriasis patients: an expert group consensus. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 27-32.	1.3	24
66	Clinical relevance of immunogenicity of biologics in psoriasis: Implications for treatment strategies. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 1424-1430.	1.3	57
67	Treatment for palmoplantar pustular psoriasis: systematic literature review, evidence-based recommendations and expert opinion. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 13-16.	1.3	57
68	Hidradenitis suppurativa after renal transplantation: Complete remission after switching from oral cyclosporine to oral tacrolimus. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, e210-e211.	0.6	12
69	Paradoxical psoriatic arthritis in a patient with rheumatoid arthritis treated by TNF± blocker. <i>Joint Bone Spine</i> , 2014, 81, 455-456.	0.8	9
70	Alopecia areata occurring during anti-TNF therapy: A national multicenter prospective study. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, 1146-1149.	0.6	66
71	Biologic targeted therapies in pediatric rheumatology. <i>Joint Bone Spine</i> , 2014, 81, 2-48.	0.8	5
72	Cutaneous Actinomycosis Associated with Anti-TNF-Alpha Therapy: Report of Two Cases. <i>Dermatology</i> , 2014, 228, 112-114.	0.9	10

#	ARTICLE	IF	CITATIONS
73	THU0165â€¦New Onset Vitiligo under Biological Agents: A CASE Series. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 237.2-237.	0.5	3
74	Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, 12-29.	1.3	248
75	Alcohol consumption and psoriasis: a systematic literature review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, 30-35.	1.3	121
76	Risk of cancer in psoriasis: a systematic review and meta-analysis of epidemiological studies. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, 36-46.	1.3	194
77	Psoriasis, cardiovascular events, cancer risk and alcohol use: evidence-based recommendations based on systematic review and expert opinion. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, 2-11.	1.3	46
78	Prognostic Factors of Paraneoplastic Pemphigus. <i>Archives of Dermatology</i> , 2012, 148, 1165.	1.7	125
79	Factors associated with 2009 monovalent H1N1 vaccine coverage: A cross sectional study of 1308 patients with psoriasis in France. <i>Vaccine</i> , 2012, 30, 5703-5707.	1.7	7
80	Successful management of severe infant bullous pemphigoid with omalizumab. <i>British Journal of Dermatology</i> , 2012, 166, 1140-1142.	1.4	54
81	Evidence-based recommendations on topical treatment and phototherapy of psoriasis: systematic review and expert opinion of a panel of dermatologists. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 1-10.	1.3	56
82	Efficacy of Psoralen UVâ€A therapy vs. Narrowband UVâ€B therapy in chronic plaque psoriasis: a systematic literature review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 11-21.	1.3	60
83	Carcinogenic risks of Psoralen UVâ€A therapy and Narrowband UVâ€B therapy in chronic plaque psoriasis: a systematic literature review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 22-31.	1.3	246
84	Ocular damage in patients with psoriasis treated by Psoralen UVâ€A therapy or Narrow band UVB therapy: a systematic literature review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 32-35.	1.3	13
85	Topical corticosteroids in plaque psoriasis: a systematic review of efficacy and treatment modalities. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 36-46.	1.3	34
86	Topical corticosteroids in plaque psoriasis: a systematic review of risk of adrenal axis suppression and skin atrophy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 47-51.	1.3	53
87	Topical vitamin D analogues alone or in association with topical steroids for psoriasis: a systematic review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 52-60.	1.3	42
88	Adherence to topical treatment in psoriasis: a systematic literature review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 61-67.	1.3	161
89	Evidence-based recommendations on conventional systemic treatments in psoriasis: systematic review and expert opinion of a panel of dermatologists. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011, 25, 2-11.	1.3	70
90	Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011, 25, 12-18.	1.3	135

#	ARTICLE	IF	CITATIONS
91	Oral cyclosporin in psoriasis: a systematic review on treatment modalities, risk of kidney toxicity and evidence for use in non-plaque psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011, 25, 19-27.	1.3	100
92	Efficacy and safety of oral retinoids in different psoriasis subtypes: a systematic literature review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011, 25, 28-33.	1.3	51
93	TNF alpha antagonist therapy and safety monitoring. <i>Joint Bone Spine</i> , 2011, 78, 15-185.	0.8	65
94	Evidence-based recommendations to assess psoriasis severity: systematic literature review and expert opinion of a panel of dermatologists. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010, 24, 2-9.	1.3	62
95	What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010, 24, 10-16.	1.3	229
96	What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literature. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010, 24, 17-22.	1.3	114
97	Cardiovascular risk factors in patients with plaque psoriasis: a systematic review of epidemiological studies. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010, 24, 23-30.	1.3	119
98	Assessment of risk of psoriatic arthritis in patients with plaque psoriasis: a systematic review of the literature. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010, 24, 31-35.	1.3	124
99	Comparative study of stress and quality of life in outpatients consulting for different dermatoses in 5 academic departments of dermatology. <i>European Journal of Dermatology</i> , 2008, 18, 412-5.	0.3	27
100	Rapid healing of long-lasting sickle cell leg ulcer treated with allogeneic keratinocytes. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2007, 21, 070209222700034-???	1.3	9
101	Psoriasis physiopathology. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2006, 20, 10-23.	1.3	11
102	Genetics of psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2006, 20, 42-51.	1.3	14
103	TGF $\beta$ 2 Inhibits CD1d Expression on Dendritic Cells. <i>Journal of Investigative Dermatology</i> , 2005, 124, 116-118.	0.3	24
104	T-Cell Modulation for the Treatment of Chronic Plaque Psoriasis with Efalizumab (Raptiva $\text{\textcircled{C}}$ ): Mechanisms of Action. <i>Dermatology</i> , 2004, 208, 297-306.	0.9	112
105	Clinicopathologic features of graft rejection of the first human hand allograft. <i>Transplantation</i> , 2003, 76, 688-693.	0.5	192
106	Angioedema and Oral Contraception. <i>Dermatology</i> , 2003, 206, 106-109.	0.9	45
107	The AT-Hook Protein D1 Is Essential for <i>Drosophila melanogaster</i> Development and Is Implicated in Position-Effect Variegation. <i>Molecular and Cellular Biology</i> , 2002, 22, 1218-1232.	1.1	51
108	Anti-laminin 5 pemphigoid and acquired haemophilia. <i>British Journal of Dermatology</i> , 2002, 146, 1105-1105.	1.4	18

#	ARTICLE	IF	CITATIONS
109	Immunohistologic studies of the skin of human hand allografts: our experience with two patients. Transplantation Proceedings, 2001, 33, 1722.	0.3	24
110	Recurrent erythema multiforme and chronic hepatitis C: efficacy of interferon alpha. British Journal of Dermatology, 2000, 142, 1248-1249.	1.4	21
111	Evidence for Human CD4+ T Cells in the CD1-Restricted Repertoire: Derivation of Mycobacteria-Reactive T Cells from Leprosy Lesions. Journal of Immunology, 2000, 164, 4790-4796.	0.4	80
112	Overexpression of CD1d by Keratinocytes in Psoriasis and CD1d-Dependent IFN- $\gamma$ Production by NK-T Cells. Journal of Immunology, 2000, 165, 4076-4085.	0.4	202
113	Induction of Early Transcription in One-Cell Mouse Embryos by Microinjection of the Nonhistone Chromosomal Protein HMG-I. Developmental Biology, 2000, 221, 337-354.	0.9	44
114	Regeneration of cutaneous innervation in a human hand allograft. Lancet, The, 2000, 356, 1738-1739.	6.3	14
115	SEQUENTIAL HISTOLOGICAL AND IMMUNOHISTOCHEMICAL STUDY OF THE SKIN OF THE FIRST HUMAN HAND ALLOGRAFT. Transplantation, 2000, 69, 1380-1385.	0.5	39
116	Microchimerism in a human hand allograft. Lancet, The, 1999, 354, 1820-1821.	6.3	22
117	CD1 : une nouvelle famille de molécules présentatrices d'antigènes aux caractéristiques singulières.. Medecine/Sciences, 1999, 15, 7.	0.0	1
118	CD1 expression by dendritic cells in human leprosy lesions: correlation with effective host immunity. Journal of Immunology, 1999, 162, 1851-8.	0.4	129
119	CD1d1 is expressed in mouse epidermis on keratinocytes and Langerhans cells. Journal of Dermatological Science, 1998, 16, S164.	1.0	0
120	Three distinct sub-nuclear populations of HMG-I protein of different properties revealed by co-localization image analysis. Journal of Cell Science, 1998, 111, 3551-3561.	1.2	37
121	Interferon-gamma differentially regulates interleukin-12 and interleukin-10 production in leprosy.. Journal of Clinical Investigation, 1997, 99, 336-341.	3.9	82
122	CD1 presentation of microbial nonpeptide antigens to T cells.. Journal of Clinical Investigation, 1997, 99, 2071-2074.	3.9	39
123	CD1: clues on a new antigen-presenting pathway. Research in Immunology, 1996, 147, 321-328.	0.9	10
124	Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis.. Journal of Clinical Investigation, 1996, 97, 2130-2138.	3.9	371
125	Toxic epidermal necrolysis after sulfasalazine treatment of mild psoriatic arthritis: Warning on the use of sulfasalazine for a new indication. Arthritis and Rheumatism, 1995, 38, 573-573.	6.7	7
126	Conductive polyethylene as sensitive layer for gas detection. Sensors and Actuators B: Chemical, 1995, 28, 75-80.	4.0	19



#	ARTICLE	IF	CITATIONS
127	A.c. and d.c. conductivities in a metal/polymer composite/metal sandwich. Case of charge-transfer "doped" polyethylene complex. Synthetic Metals, 1994, 66, 197-202.	2.1	2
128	Mécanique et régulation de la migration kératinocytaire. Medecine/Sciences, 1993, 9, 403.	0.0	0
129	Keratinocyte Migration Is Partially Supported by the Cell-Binding Domain of Fibronectin and Is RGDS-Dependent. Journal of Investigative Dermatology, 1992, 99, 656-659.	0.3	14
130	Barrier properties of conducting poly(ethylene) with gold and silicon. Sensors and Actuators A: Physical, 1992, 33, 85-89.	2.0	6